

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To:

GlaxoSmithKline Services Unlimited
Attn. Rutter, Keith
980 Great West Road
Brentford
Middlesex TW8 9GS
UNITED KINGDOM

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT AND
THE WRITTEN OPINION OF THE INTERNATIONAL
SEARCHING AUTHORITY, OR THE DECLARATION

**GlaxoSmithKline
Corporate IP
Received BRENTFORD**

(PCT Rule 44.1)

28 FEB 2005

Date of mailing
(day/month/year)

28/02/2005

Applicant's or agent's file reference:

DES-PB60531

ADMIN:

PM: N/A

ON

UPDATED ON:

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International application No.

PCT/EP2004/011366

ATTY CHECKED/FILE

International filing date

(day/month/year)

06/10/2004

Applicant

GLAXO GROUP LIMITED

1. ☒ The applicant is hereby notified that the international search report and the written opinion of the International Searching Authority have been established and are transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO, 34 chemin des Colombettes
1211 Geneva 20, Switzerland, Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith.

3. ☐ **With regard to the protest** against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

- ☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.
☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. Reminders

Shortly after the expiration of **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.

Within **19 months** from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until **30 months** from the priority date (in some Offices even later); otherwise, the applicant must, **within 20 months** from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

In respect of other designated Offices, the time limit of **30 months** (or later) will apply even if no demand is filed within 19 months.

See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the *PCT Applicant's Guide*, Volume II, National Chapters and the WIPO Internet site.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Federico Bonomelli

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the International application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference DES-PB60531	FOR FURTHER ACTION <small>see Form PCT/ISA/220 as well as, where applicable, item 5 below.</small>	
International application No. PCT/EP2004/011366	International filing date (day/month/year) 06/10/2004	(Earliest) Priority Date (day/month/year) 08/10/2003
Applicant GLAXO GROUP LIMITED		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 9 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ The international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. ☐ With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.

2. ☐ **Certain claims were found unsearchable** (See Box II).

3. ☐ **Unity of invention is lacking** (see Box III).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. With regard to the **drawings**,

a. the figure of the **drawings** to be published with the abstract is Figure No. _____

☐ as suggested by the applicant.


☐ as selected by this Authority, because the applicant failed to suggest a figure.

☐ as selected by this Authority, because this figure better characterizes the invention.

b. ☐ none of the figures is to be published with the abstract.

Box No. IV Text of the abstract (Continuation of Item 5 of the first sheet)

Compounds of formula (I) or a pharmaceutically acceptable derivative thereof:



(I)

wherein A, B, D, Z, R¹, R^{2a}, R^{2b}, and R^x are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in treating conditions mediated by the action of PGE₂ at EP₁ receptors. Such conditions include pain, or inflammatory, immunological, bone, neurodegenerative or renal disorders.

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D207/337 C07D231/12 C07D241/12 C07D307/46 C07D213/55
 C07D213/56 C07D401/04 A61K31/341 A61K31/402 A61K31/415
 A61K31/4418 A61K31/4439 A61K31/4965 A61P13/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 492 411 B1 (TALLEY JOHN J ET AL) 10 December 2002 (2002-12-10) claims and examples 40,47,48,77 -----	1-14
X	EP 0 647 629 A (SANOFI) 12 April 1995 (1995-04-12) claims and examples (e.g. tables 1 and 2) -----	1-14
X	US 5 723 483 A (LABEEUW ET AL) 3 March 1998 (1998-03-03) claims and examples (e.g. table 6) -----	1-14
X	WO 01/19814 A2 (MERCK FROSST CANADA & CO; LACOMBE, PATRICK; LABELLE, MARC; RUEL, REJEA) 22 March 2001 (2001-03-22) cited in the application the whole document ----- -/--	1-14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

1 February 2005

Date of mailing of the international search report

28/02/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Gregoire, A

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 270 559 A (J. URIACH & CIA. S.A) 2 January 2003 (2003-01-02) the whole document	1-14
X	EP 0 752 421 A (ZENECA LIMITED) 8 January 1997 (1997-01-08) cited in the application the whole document	1-14
X	et al M ABDUR RAHIM, P N PRAVEEN RAO AND EDWARD E KNAUS: "Isomeric acetoxy analogues of Rofecoxib: a novel class of highly potent and selective cyclooxygenase-2 inhibitors" <u>BIOORGANIC AND MEDICINAL CHEMISTRY</u> <u>LETTERS</u> , vol. 12, 2002, pages 2753-2756, XP002315466 compound 15A	1-3,6-14
X	DATABASE CAPLUS 'Online! <u>CHEMICAL ABSTRACTS SERVICE, COLUMBUS,</u> <u>OHIO, US;</u> <u>PATHAN, M. D. ET AL:</u> "2-Aryl-3-(2'-p-chlorophenyl-1',3',4'-oxad iazol-5'-ylphenyl)-4- thiazolidinones" XP002315470 retrieved from STN Database accession no. <u>2001:514183</u> compound with RN 361342-29-2 abstract & <u>JOURNAL OF THE INSTITUTION OF CHEMISTS</u> (INDIA), 72(5), 190-191 CODEN: <u>JOICAZ</u> ; ISSN: 0020-3254, 2000,	1-3,6,7
X	G S TRIVEDI, N C DESAI: "Synthesis and antimicrobial activity of some 4-thiazolidinones" <u>INDIAN JOURNAL OF CHEMISTRY</u> , vol. 31B, 1992, pages 366-369, XP009043257 compound IVG	1-3,6,7
X	GUNTER KARIG, JAMES A SPENCER AND TIMOTHY GALLAGHER: "Direct deprotonation-transmetalation as a route to substituted pyridines" <u>ORGANIC LETTERS</u> , 2001, pages 835-838, XP002315468 compound 9A	1-3

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SAUL H. ROSENBERG ^{et al} AND HENRY RAPOPORT: "Convergent and efficient synthesis of spiro'benzofuran-3(2H),4'-piperidines!" J. ORG. CHEM., 1984, pages 56-62, XP002315467 compounds 12, 17	1-3
X	ANNE-SOPHIE REBSTOCK, FLORENCE MONGIN, FRANÇOIS TRE COURT AND GUY QUEGUINER: "Synthesis and deprotonation of 2-(pyridyl)phenols and 2-(pyridyl)anilines" ORG. BIOMOL. CHEM., vol. 1, 18 July 2003 (2003-07-18), pages 3064-3068, XP002315469 compound 13	1-3
P, X	WO 03/101959 A1 (GLAXO GROUP LIMITED; GIBLIN, GERARD, MARTIN, PAUL; HALL, ADRIAN; HEALY) 11 December 2003 (2003-12-11) cited in the application the whole document	1-14
P, X	WO 2004/083185 A2 (GLAXO GROUP LIMITED; GIBLIN, GERARD, MARTIN, PAUL; HALL, ADRIAN; LEWEL) 30 September 2004 (2004-09-30) the whole document	1-14

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/011366

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 9-11 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6492411	B1	10-12-2002	US 6413960 B1 02-07-2002
			US 6156781 A 05-12-2000
			US 5760068 A 02-06-1998
			US 5521207 A 28-05-1996
			US 5466823 A 14-11-1995
			US 6586603 B1 01-07-2003
			US 6716991 B1 06-04-2004
			US 2004192930 A1 30-09-2004
			AT 187965 T 15-01-2000
			AU 690609 B2 30-04-1998
			AU 1171495 A 19-06-1995
			CA 2177576 A1 08-06-1995
			DE 10075033 I1 18-01-2001
			DE 69422306 D1 27-01-2000
			DE 69422306 T2 18-05-2000
			DK 731795 T3 15-05-2000
			DK 922697 T3 10-06-2003
			EP 0731795 A1 18-09-1996
			FI 962249 A 29-05-1996
			GR 3032696 T3 30-06-2000
			HK 1013649 A1 07-07-2000
			JP 3025017 B2 27-03-2000
			JP 9506350 T 24-06-1997
			KR 229343 B1 01-11-1999
			KR 263817 B1 16-08-2000
			KR 261669 B1 15-07-2000
			LU 90698 A9 13-02-2001
			NL 300024 I1 02-01-2001
			NO 962184 A 29-05-1996
			NZ 276885 A 30-08-1999
			PL 314695 A1 16-09-1996
			RO 118291 B1 30-04-2003
			RU 2139281 C1 10-10-1999
			TW 418193 B 11-01-2001
			TW 467900 B 11-12-2001
			AT 212985 T 15-02-2002
			AT 233245 T 15-03-2003
			AT 219937 T 15-07-2002
			CA 2276945 A1 08-06-1995
			CA 2276946 A1 08-06-1995
			CA 2277954 A1 08-06-1995
			CN 1141630 A ,C 29-01-1997
			CN 1280125 A ,C 17-01-2001
			CN 1280126 A ,C 17-01-2001
			CY 2237 A 04-07-2003
			CZ 9601503 A3 11-12-1996
			DE 69429836 D1 21-03-2002
			DE 69429836 T2 18-07-2002
			DE 69430930 D1 08-08-2002
			DE 69430930 T2 20-02-2003
EP 0647629	A	12-04-1995	FR 2711140 A1 21-04-1995
			AT 181911 T 15-07-1999
			AU 705008 B2 13-05-1999
			AU 4186997 A 22-01-1998
			AU 685154 B2 15-01-1998
			AU 7575394 A 04-05-1995
			CA 2117821 A1 13-04-1995

Information on patent family members

PCT/EP2004/011366

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0647629	A		CN	1108651 A	20-09-1995
			DE	69419377 D1	12-08-1999
			EP	0647629 A1	12-04-1995
			FI	944770 A	13-04-1995
			HU	70048 A2	28-09-1995
			JP	7278114 A	24-10-1995
			NO	943837 A	18-04-1995
			NZ	264661 A	27-08-1996
			RU	2140912 C1	10-11-1999
			US	5502059 A	26-03-1996
			US	5585497 A	17-12-1996
			US	5523455 A	04-06-1996
			ZA	9407957 A	22-05-1995
US 5723483	A	03-03-1998	FR	2732967 A1	18-10-1996
			AU	709119 B2	19-08-1999
			AU	5651696 A	30-10-1996
			CA	2220827 A1	17-10-1996
			CN	1184469 A ,C	10-06-1998
			CZ	9703232 A3	18-02-1998
			EE	9700264 A	15-04-1998
			EP	1097921 A1	09-05-2001
			EP	0820444 A1	28-01-1998
			WO	9632382 A1	17-10-1996
			HU	9801435 A2	28-10-1998
			IN	185700 A1	07-04-2001
			JP	3061644 B2	10-07-2000
			JP	11504624 T	27-04-1999
			NO	974702 A	10-12-1997
			NZ	307227 A	28-01-2000
			PL	322723 A1	16-02-1998
			RU	2195455 C2	27-12-2002
			SK	136797 A3	08-07-1998
			TR	9701146 T1	21-02-1998
			TW	411332 B	11-11-2000
			US	6172239 B1	09-01-2001
			US	5965579 A	12-10-1999
			US	5925661 A	20-07-1999
			US	5936123 A	10-08-1999
			US	5939449 A	17-08-1999
			ZA	9602886 A	15-10-1996
WO 0119814	A2	22-03-2001	AT	259795 T	15-03-2004
			AU	776831 B2	23-09-2004
			AU	7264200 A	17-04-2001
			CA	2384783 A1	22-03-2001
			DE	60008399 D1	25-03-2004
			DE	60008399 T2	09-12-2004
			EP	1216238 A2	26-06-2002
			ES	2213601 T3	01-09-2004
			JP	2003509419 T	11-03-2003
			US	6369084 B1	09-04-2002
EP 1270559	A	02-01-2003	ES	2159489 A1	01-10-2001
			AU	3931101 A	03-10-2001
			BR	0109445 A	03-06-2003
			CA	2403732 A1	20-09-2002
			EP	1270559 A1	02-01-2003

Information on patent family members

PCT/EP2004/011366

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
EP 1270559	A	JP 2003528086 T	24-09-2003	
		MX PA02009322 A	12-03-2003	
		NO 20024504 A	22-11-2002	
		US 2003176481 A1	18-09-2003	
		WO 0170704 A1	27-09-2001	
EP 0752421	A	08-01-1997	EP 0752421 A1	08-01-1997
			JP 9040607 A	10-02-1997
			US 6057345 A	02-05-2000
			US 2003139418 A1	24-07-2003
			US 5834468 A	10-11-1998
WO 03101959	A1	11-12-2003	NONE	
WO 2004083185	A2	30-09-2004	NONE	